ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 170 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,522 | +60.4% | 6,224 | +207.2% | 0.00% | +100.0% |
| Q2 2023 | $43,356 | +94152.2% | 2,026 | +80.1% | 0.00% | 0.0% |
| Q1 2023 | $46 | +206.7% | 1,125 | +235.8% | 0.00% | 0.0% |
| Q4 2022 | $15 | -100.0% | 335 | -94.5% | 0.00% | -80.0% |
| Q3 2022 | $319,000 | -44.7% | 6,145 | -49.7% | 0.01% | -61.5% |
| Q2 2022 | $577,000 | -23.8% | 12,216 | +14.9% | 0.01% | +85.7% |
| Q1 2022 | $757,000 | +232.0% | 10,628 | +249.0% | 0.01% | +75.0% |
| Q4 2021 | $228,000 | +188.6% | 3,045 | +120.3% | 0.00% | +100.0% |
| Q3 2021 | $79,000 | +29.5% | 1,382 | -0.6% | 0.00% | 0.0% |
| Q2 2021 | $61,000 | -27.4% | 1,391 | -17.8% | 0.00% | +100.0% |
| Q1 2021 | $84,000 | +115.4% | 1,692 | +83.9% | 0.00% | 0.0% |
| Q4 2020 | $39,000 | -36.1% | 920 | -30.9% | 0.00% | 0.0% |
| Q3 2020 | $61,000 | -59.6% | 1,331 | -55.9% | 0.00% | -83.3% |
| Q2 2020 | $151,000 | +738.9% | 3,017 | +915.8% | 0.01% | +500.0% |
| Q3 2019 | $18,000 | +20.0% | 297 | +84.5% | 0.00% | 0.0% |
| Q1 2019 | $15,000 | – | 161 | +16000.0% | 0.00% | – |
| Q3 2018 | $0 | -100.0% | 1 | -99.7% | 0.00% | -100.0% |
| Q1 2017 | $11,000 | -69.4% | 364 | -66.0% | 0.00% | -75.0% |
| Q4 2016 | $36,000 | +414.3% | 1,070 | +256.7% | 0.00% | +300.0% |
| Q2 2016 | $7,000 | +16.7% | 300 | +44.9% | 0.00% | 0.0% |
| Q1 2016 | $6,000 | 0.0% | 207 | +23.2% | 0.00% | 0.0% |
| Q4 2015 | $6,000 | -89.5% | 168 | -86.7% | 0.00% | -80.0% |
| Q2 2015 | $57,000 | -46.2% | 1,260 | -63.4% | 0.01% | -61.5% |
| Q1 2015 | $106,000 | +5200.0% | 3,447 | +8738.5% | 0.01% | – |
| Q4 2014 | $2,000 | -88.2% | 39 | -90.0% | 0.00% | -100.0% |
| Q2 2014 | $17,000 | -10.5% | 391 | -18.9% | 0.00% | 0.0% |
| Q1 2014 | $19,000 | +11.8% | 482 | -22.1% | 0.00% | -33.3% |
| Q4 2013 | $17,000 | -67.9% | 619 | -73.3% | 0.00% | -50.0% |
| Q3 2013 | $53,000 | -56.6% | 2,315 | -66.4% | 0.01% | -40.0% |
| Q2 2013 | $122,000 | – | 6,895 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 624,768 | $29,533,000 | 9.76% |
| Fairmount Funds Management LLC | 469,264 | $22,182,000 | 5.08% |
| Foresite Capital Opportunity Management V, LLC | 22,750 | $1,075,000 | 2.71% |
| ARMISTICE CAPITAL, LLC | 2,070,000 | $97,849,000 | 1.71% |
| Paradigm Biocapital Advisors LP | 148,216 | $7,006,000 | 1.40% |
| Foresite Capital Management V, LLC | 42,250 | $1,997,000 | 1.40% |
| RA Capital Management | 896,724 | $42,389,000 | 1.13% |
| TANG CAPITAL MANAGEMENT LLC | 137,700 | $6,509,000 | 0.99% |
| Soleus Capital Management, L.P. | 100,000 | $4,727,000 | 0.74% |
| ACUTA CAPITAL PARTNERS, LLC | 27,500 | $1,300,000 | 0.72% |